Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 3 de 3
1.
Dtsch Med Wochenschr ; 148(7): 396-399, 2023 03.
Article De | MEDLINE | ID: mdl-36940690

ANAMNESIS AND CLINICAL EXAMINATION: A 40-year-old male patient presented to our emergency department with a new onset of hemorrhagic diathesis. Clinically, there were marked bleeding stigmata with extensive ecchymosis in the thigh area and oral mucosal hemorrhage with otherwise general well-being. DIAGNOSTICS: The coagulation diagnostics performed were consistent with the picture of disseminated intravascular consumption coagulopathy. Microscopic blood count also revealed 74% morphologically atypical promyelocytes. DIAGNOSIS, THERAPY, AND CLINICAL COURSE: Bone marrow investigation confirmed the diagnosis of a microgranular variant of acute promyelocytic leukemia. In addition to coagulation optimization, therapy with all-trans retinoic acid (ATRA) was initiated immediately. Subsequently, arsenic trioxide (ATO) and the anthracycline idarubicin were added. No severe complications occurred in the following course of treatment. Moreover, the patient is currently in complete remission regarding acute promyelocytes leukemia. CONCLUSIONS: Acute promyelocytic leukemia accounts for approximately 10-15% of all acute myeloid leukemias. Often, association with marked coagulation abnormalities due to disseminated intravascular consumption coagulopathy, which is present at diagnosis, APL becomes fatal if untreated. Rapid therapy initiation with ATRA and coagulation optimization, initiated as soon as the diagnosis is suspected, are crucial for prognosis.


Disseminated Intravascular Coagulation , Leukemia, Promyelocytic, Acute , Male , Humans , Adult , Leukemia, Promyelocytic, Acute/diagnosis , Leukemia, Promyelocytic, Acute/drug therapy , Vitamin A/therapeutic use , Disseminated Intravascular Coagulation/diagnosis , Disseminated Intravascular Coagulation/complications , Disseminated Intravascular Coagulation/drug therapy , Arsenic Trioxide/therapeutic use , Tretinoin/adverse effects , Antineoplastic Combined Chemotherapy Protocols/therapeutic use
...